Peptide Proof

What Is a Peptide, in Plain English?

Wed, 09 Sep 2026 12:00:00 +0000

A peptide is a short chain of amino acids that carries a message. This 60-second brief covers what that means, which peptides the body already makes, and why researchers modify them.

Semaglutide: What the Published Trials Actually Found

Wed, 09 Sep 2026 12:00:00 +0000

Two trials, the numbers, and the side effects. STEP 1 measured weight over 68 weeks. SELECT measured heart attacks and strokes over about three years. No hype, just what was reported.

What Side Effects Were Actually Reported in the Trials?

Wed, 09 Sep 2026 12:00:00 +0000

Semaglutide and tirzepatide are prescription medications, FDA-approved for type 2 diabetes and for chronic weight management.

What Does BPC-157 Actually Do? What the Research Shows

Wed, 09 Sep 2026 12:00:00 +0000

BPC-157 is one of the most talked-about peptides online, so it is worth asking plainly what the published research shows. It is a synthetic chain of fifteen amino acids, based on a fragment of a protein found in human gastric juice.

What Does "Research Use Only" Actually Mean?

Wed, 09 Sep 2026 12:00:00 +0000

Research Use Only sounds like a safety grade. It is not. It is a labelling and marketing category that began with laboratory reagents, antibodies, assay kits and cell lines sold to labs for developing other tests.

Does Creatine Still Work After 50?

Wed, 09 Sep 2026 12:00:00 +0000

Creatine is one of the best-studied supplements in sports nutrition, and the general evidence for it alongside resistance training is strong. The open question is whether that holds after fifty, when muscle responds less readily to training and nutrition.

Does Sleep Quality Affect Tissue Repair and Injury Risk?

Wed, 09 Sep 2026 12:00:00 +0000

Sleep is when the body does much of its repair work, so it is fair to ask whether short or poor sleep shows up later as injury. For injury risk, the research is surprisingly consistent. For tissue repair itself, the human evidence is thin.

Amino Acids, Peptides, Proteins: What's the Difference?

Wed, 09 Sep 2026 12:00:00 +0000

Amino acids, peptides and proteins get used almost interchangeably online, but they are three sizes of the same thing. An amino acid is a single building block.

Is 'Food Noise' a Real, Measurable Thing?

Wed, 09 Sep 2026 12:00:00 +0000

"Food noise" is not a clinical term. It came from patients and clinicians describing what changed when they started a GLP-1 medication: the constant background chatter about food went quiet.

What Does TB-500 Actually Do? What the Research Shows

Wed, 09 Sep 2026 12:00:00 +0000

TB-500 is usually sold as a recovery peptide for tendon, ligament and muscle injuries. To understand the research, you first have to understand what it is. TB-500 is not something the body makes.

Why 'It Worked in Mice' Usually Means Nothing

Wed, 09 Sep 2026 12:00:00 +0000

A striking animal result is where a lot of health claims begin, and BPC-157 shows why that is a starting line, not a finish.

Why Does Building Muscle Get Harder With Age?

Wed, 09 Sep 2026 12:00:00 +0000

Muscle loss is usually framed as something that happens abruptly in old age. The physiology says otherwise.

Is 'Brain Fog' a Real, Measurable Thing?

Wed, 09 Sep 2026 12:00:00 +0000

'Brain fog' is a patient's phrase, not a diagnosis. There is no ICD or DSM code for it, no blood test, and no single validated questionnaire.

How a Receptor Works: The Lock-and-Key Idea

Wed, 09 Sep 2026 12:00:00 +0000

Almost every peptide story eventually comes back to a receptor, so it is worth knowing what one is. A receptor is a protein, most often embedded in the outer membrane of a cell. One end faces outward into the blood or the fluid around the cell.

How Much of the Weight Lost on GLP-1s Is Muscle?

Wed, 09 Sep 2026 12:00:00 +0000

Semaglutide, tirzepatide, liraglutide and dulaglutide are prescription medications approved for type 2 diabetes and, in some cases, chronic weight management. A common worry is that the weight they help people lose is partly muscle.

What Does GHK-Cu Actually Do? What the Research Shows

Wed, 09 Sep 2026 12:00:00 +0000

GHK-Cu shows up in skincare aisles and research-peptide listings alike, so it helps to separate what is known from what is claimed.

How to Spot a Bad Health Claim

Wed, 09 Sep 2026 12:00:00 +0000

A health claim does not need to be a lie to mislead. It only needs to skip a step a careful reader would ask about. Four real studies make each step concrete, and together they form a checklist you can run on almost any headline.

How Much Protein Do Older Adults Actually Need?

Wed, 09 Sep 2026 12:00:00 +0000

The recommended dietary allowance for protein is 0.8 grams per kilogram of body weight per day. Whether older adults need more than that is one of the most argued questions in nutrition, and the answer from the trials depends on who is being measured.

How Long Does Soft Tissue Actually Take to Heal?

Wed, 09 Sep 2026 12:00:00 +0000

Symptoms fade well before the biology finishes. That is the short version of the healing-timeline literature, and it holds across tendon, ligament and muscle, though the actual clocks are very different.

Why Most Peptides Can't Survive Your Stomach

Wed, 09 Sep 2026 12:00:00 +0000

Peptides are short chains of amino acids, and that is exactly the kind of molecule the digestive system exists to dismantle. Food protein is peptide chains too.

What Does Ipamorelin Actually Do? What the Research Shows

Wed, 09 Sep 2026 12:00:00 +0000

Ipamorelin is a synthetic pentapeptide, a chain of five amino acids designed in a laboratory rather than copied from a human hormone.

How to Read a Clinical Trial

Wed, 09 Sep 2026 12:00:00 +0000

A clinical trial is built around one question chosen before it starts. That is the primary endpoint, and it is meant to be locked into a public registration so it cannot be swapped for a better-looking result later.

What Is Sarcopenia and How Is It Actually Measured?

Wed, 09 Sep 2026 12:00:00 +0000

Sarcopenia is the age-related loss of muscle, but for most of its history there was no agreed way to diagnose it.

How Does Poor Sleep Affect Metabolic Health?

Wed, 09 Sep 2026 12:00:00 +0000

The link between short sleep and metabolic trouble is usually discussed as a long-term population statistic. A cluster of small, tightly controlled trials shows the effect is faster and more direct than that.

What 'Half-Life' Means and Why It Matters for Peptides

Wed, 09 Sep 2026 12:00:00 +0000

Half-life is one of those terms that gets thrown around in peptide discussions as if everyone agrees what it means. The definition is simple: it is the time it takes for the concentration of a substance in the blood to fall by half.

Why Does Weight Come Back After Stopping Semaglutide?

Wed, 09 Sep 2026 12:00:00 +0000

Semaglutide is a prescription medication approved for type 2 diabetes and for chronic weight management. It works by acting on GLP-1 receptors, lowering appetite and slowing how quickly the stomach empties, for as long as the drug is present in the body.

What Does CJC-1295 Actually Do? What the Research Shows

Wed, 09 Sep 2026 12:00:00 +0000

CJC-1295 is a synthetic, chemically modified version of growth hormone releasing hormone, or GHRH, the natural signal the hypothalamus sends to the pituitary gland to release growth hormone.

What Makes a Control Group Good — or Useless?

Wed, 09 Sep 2026 12:00:00 +0000

A control group exists to answer one question: compared to what would have happened anyway, did the treatment do anything? Several things make a person report feeling better that have nothing to do with a treatment's biology. Natural healing.

Does Resistance Training Work as Well After 60?

Wed, 09 Sep 2026 12:00:00 +0000

The most famous answer to this question comes from a tiny 1990 trial. Fiatarone and colleagues, publishing in JAMA, put ten nursing-home residents averaging ninety years old through eight weeks of high-intensity resistance training. Nine finished.

Does Stretching Prevent Injury?

Wed, 09 Sep 2026 12:00:00 +0000

Stretching before exercise is one of the most widespread habits in sport, and it comes with an assumption: it keeps you from getting hurt.

What 'FDA-Approved' Actually Means (and Doesn't)

Wed, 09 Sep 2026 12:00:00 +0000

The phrase 'FDA-approved' gets attached to a lot of things it does not belong to. The FDA's own consumer page, titled 'Is It Really FDA Approved?', is the cleanest place to start.

Semaglutide vs Tirzepatide: What Do Head-to-Head Trials Show?

Wed, 09 Sep 2026 12:00:00 +0000

Semaglutide and tirzepatide are both prescription medications approved for type 2 diabetes and chronic weight management. Semaglutide acts on the GLP-1 receptor; tirzepatide acts on both the GLP-1 and GIP receptors.

What Does Sermorelin Actually Do? What the Research Shows

Wed, 09 Sep 2026 12:00:00 +0000

Sermorelin is a synthetic copy of the first 29 amino acids of human growth hormone releasing hormone, the signal the hypothalamus sends to the pituitary gland.

Relative vs. Absolute Risk: The Most Common Trick in Health Headlines

Wed, 09 Sep 2026 12:00:00 +0000

A trial result can be reported two ways, and which one a headline picks changes how big the effect sounds. Relative risk reduction is a ratio, how much smaller one group's risk is than the other's, and ratios look large even when both risks are small.

What Does Grip Strength Actually Predict?

Wed, 09 Sep 2026 12:00:00 +0000

Grip strength is one of the simplest measurements in medicine: squeeze a handheld device as hard as you can. What makes it interesting is how consistently that number tracks survival in very large groups of people.

What Does Sleep Deprivation Do to Hormones?

Wed, 09 Sep 2026 12:00:00 +0000

A series of small, tightly controlled laboratory trials, most of them run at the University of Chicago over the past 25 years, shows that cutting sleep disrupts several hormone systems within days rather than months.

What Is a Compounded Drug?

Wed, 09 Sep 2026 12:00:00 +0000

Compounding is one of the oldest jobs in pharmacy, and one of the least understood. The FDA defines it as combining, mixing or altering ingredients to create a medication tailored to the needs of an individual patient.

How Much Weight Do People Actually Lose Outside of Clinical Trials?

Wed, 09 Sep 2026 12:00:00 +0000

The headline numbers from the pivotal trials are well known. In STEP 1, published in the New England Journal of Medicine in 2021, 1,961 adults on weekly semaglutide lost an average of 14.9 percent of body weight over 68 weeks, against 2.4 percent on placebo.

What Does Tesamorelin Actually Do? What the Research Shows

Wed, 09 Sep 2026 12:00:00 +0000

Tesamorelin is a synthetic, stabilized analog of growth hormone releasing hormone, the hypothalamic signal that tells the pituitary to release growth hormone.

What 'Statistically Significant' Actually Means

Wed, 09 Sep 2026 12:00:00 +0000

Statistically significant is one of the most quoted and least understood phrases in health news.

Is 'Muscle Memory' Real?

Wed, 09 Sep 2026 12:00:00 +0000

Muscle memory, the idea that a previously trained muscle regains size faster than an untrained one gains it, is widely believed.

Do NSAIDs Slow Tendon and Bone Healing?

Wed, 09 Sep 2026 12:00:00 +0000

Nonsteroidal anti-inflammatory drugs work by blocking cyclooxygenase enzymes that drive inflammation. Because inflammation is also an early step in tissue repair, researchers have long asked whether these drugs get in the way of healing.

Phase 1, 2, 3: What Trial Phases Mean

Wed, 09 Sep 2026 12:00:00 +0000

When a headline says a peptide 'passed a phase 2 trial', the phase number carries most of the meaning. The FDA's drug development pages describe the phases plainly.

Why Am I Still Hungry on a GLP-1?

Wed, 09 Sep 2026 12:00:00 +0000

GLP-1 receptor agonists such as semaglutide, liraglutide and tirzepatide are prescription medications, and one of their most consistent effects is a drop in appetite. Several trials have measured that directly rather than just tracking the scale.

What Does MK-677 Actually Do? What the Research Shows

Wed, 09 Sep 2026 12:00:00 +0000

MK-677, known generically as ibutamoren, is different from most compounds in the peptide world in one basic way: it is not a peptide.

What Is an Effect Size, and Why Does It Matter More Than the P-Value?

Wed, 09 Sep 2026 12:00:00 +0000

A p-value and an effect size answer two different questions.

Does Protein Timing Matter, or Just Total Intake?

Wed, 09 Sep 2026 12:00:00 +0000

Protein timing is argued over endlessly, so it is worth being precise about what a clean test looks like. To isolate timing, a trial has to hold total daily protein constant and change only how it is divided across the day.

Does Creatine Do Anything for the Brain?

Wed, 09 Sep 2026 12:00:00 +0000

Creatine's best-known job is in muscle, where it buffers the phosphocreatine system that powers short bursts of effort.

What Is GLP-1, the Hormone Your Gut Already Makes?

Wed, 09 Sep 2026 12:00:00 +0000

GLP-1 was a hormone long before it was a headline. The name stands for glucagon-like peptide-1, and it is a short peptide of roughly thirty amino acids cut from a larger parent protein called proglucagon.

What Happens to Metabolic Rate During Rapid Weight Loss?

Wed, 09 Sep 2026 12:00:00 +0000

When a body loses weight, it burns fewer calories at rest. Some of that is simple arithmetic: less tissue needs less energy.

What Does Semax Actually Do? What the Research Shows

Wed, 09 Sep 2026 12:00:00 +0000

Semax is a synthetic seven-amino-acid peptide. It is built from a fragment of adrenocorticotropic hormone, ACTH 4-10, with a three-amino-acid Pro-Gly-Pro tail added on.

How Small Is Too Small? Sample Size, Explained

Wed, 09 Sep 2026 12:00:00 +0000

How many people does a study need? There is no fixed number. Sample size is about matching the sample to the size of the effect being chased and how much variability surrounds it. A large, consistent effect can be detected in a small group.

What Do Growth Hormone Secretagogues Actually Do?

Wed, 09 Sep 2026 12:00:00 +0000

Growth hormone secretagogues are compounds that prompt the pituitary gland to release more of the body's own growth hormone. Names that circulate include ipamorelin, CJC-1295, sermorelin and MK-677. None of those is approved for human use.

What Is the Evidence for PRP in Tendon Injury?

Wed, 09 Sep 2026 12:00:00 +0000

Platelet-rich plasma, or PRP, is made by drawing a person's own blood, spinning it to concentrate the platelets, and injecting the result into an injured tendon.

What Growth Hormone Actually Does in Adults

Wed, 09 Sep 2026 12:00:00 +0000

Growth hormone does not stop mattering when growth stops. It is a 191-amino-acid peptide made by the pituitary gland and released in pulses through the day, with the largest pulse arriving shortly after sleep begins.

Does Resistance Training Protect Muscle During GLP-1 Weight Loss?

Wed, 09 Sep 2026 12:00:00 +0000

Semaglutide, tirzepatide and liraglutide are prescription medications, and a recurring concern is that some of the weight they take off is lean mass rather than fat. The obvious follow-up question is whether resistance training changes that.

What Does Selank Actually Do? What the Research Shows

Wed, 09 Sep 2026 12:00:00 +0000

Selank is a synthetic seven-amino-acid peptide modeled on tuftsin, a naturally occurring immune-signaling peptide. It was developed in Russia, where it is marketed as an anti-anxiety nasal spray, and it is also known by the developmental code name TP-7.

What Is a Systematic Review, and Why Does It Outrank a Single Study?

Wed, 09 Sep 2026 12:00:00 +0000

In 1999, the Lancet published the GISSI-Prevenzione trial: 11,324 people who had survived a recent heart attack, randomized to fish oil, vitamin E, both, or neither, and followed for three and a half years.

What Happens to Muscle During Bed Rest or Immobilisation?

Wed, 09 Sep 2026 12:00:00 +0000

Muscle does not wait weeks to notice it is not being used. A trial designed to measure how fast disuse atrophy begins, by Wall and colleagues in Acta Physiologica in 2013, put twenty-four healthy young men in a full leg cast for either five or fourteen days.

Does Magnesium Help You Sleep?

Wed, 09 Sep 2026 12:00:00 +0000

Magnesium is a mineral involved in hundreds of reactions in the body, including the NMDA and GABA signaling systems that regulate sleep. That plausible mechanism, plus low cost, has made it one of the most widely sold sleep supplements.

Hormone vs Peptide: Are They the Same Thing?

Wed, 09 Sep 2026 12:00:00 +0000

The words 'peptide' and 'hormone' get used interchangeably in a lot of health content, and that is where a lot of confusion starts. They describe different things. One is about structure. The other is about function.

How Long Do People Actually Stay on GLP-1s?

Wed, 09 Sep 2026 12:00:00 +0000

Clinical trials of semaglutide, tirzepatide and liraglutide, all prescription medications, run on fixed schedules with built-in follow-up and strong incentives to stay enrolled.

What Does DSIP Actually Do? What the Research Shows

Wed, 09 Sep 2026 12:00:00 +0000

DSIP stands for delta sleep-inducing peptide. It is a synthetic chain of nine amino acids, first identified in the 1970s in the blood of rabbits during electrically induced sleep, which is where the name comes from.

Who Funded the Study, and How Do You Find Out?

Wed, 09 Sep 2026 12:00:00 +0000

A funding source does not determine whether a result is true. Industry-funded trials are frequently well designed and independently replicated, and independently funded studies are not automatically free of bias.

Does HMB Preserve Muscle During Weight Loss or Bed Rest?

Wed, 09 Sep 2026 12:00:00 +0000

HMB, short for beta-hydroxy-beta-methylbutyrate, is a metabolite of the amino acid leucine. The question of whether it protects muscle gets two different answers depending on why the muscle is being lost.

What Actually Speeds Up Fracture Healing?

Wed, 09 Sep 2026 12:00:00 +0000

Fracture healing runs on its own biological timeline, and remarkably few interventions have been shown to shorten it. The evidence is clearer about what gets in the way than about what helps.

What a Certificate of Analysis Tells You (and What It Can't)

Wed, 09 Sep 2026 12:00:00 +0000

A certificate of analysis, or COA, sounds authoritative. It is a document issued by a laboratory that reports the results of defined tests on a defined batch of material. It describes what was measured, on what, and what the numbers were.

Do GLP-1s Affect Bone Density?

Wed, 09 Sep 2026 12:00:00 +0000

Semaglutide, tirzepatide and liraglutide are prescription medications, and rapid weight loss from any cause can cost bone. So whether these drugs affect bone density is a fair question.

What Does Epitalon Actually Do? What the Research Shows

Wed, 09 Sep 2026 12:00:00 +0000

Epitalon, also spelled Epithalon, is a synthetic peptide of four amino acids: Ala-Glu-Asp-Gly. It was designed to reproduce the amino acid makeup of Epithalamin, an older preparation extracted from animal pineal gland tissue.

Preprints, Peer Review, and What the Difference Is Worth

Wed, 09 Sep 2026 12:00:00 +0000

A preprint is a complete manuscript posted to a public server such as medRxiv, bioRxiv or Research Square, usually when it is submitted to a journal or sometimes before.

Does Testosterone Therapy Build Muscle in Older Men?

Wed, 09 Sep 2026 12:00:00 +0000

Testosterone is a prescription medication, and the randomised evidence on muscle in older men does not give one answer. It gives four, depending on who was enrolled and what was measured.

Do Omega-3 Supplements Improve Cognition?

Wed, 09 Sep 2026 12:00:00 +0000

Fish oil is one of the most popular supplements sold for brain health, backed by observational studies linking fish intake to lower dementia risk.

Why Peptide Research Is Mostly Done in Rats

Wed, 09 Sep 2026 12:00:00 +0000

Scroll through the studies on almost any research peptide and a pattern shows up fast: rats, mice, rats. That is not an accident, and not a sign the research is bad.

What Happens to Blood Sugar After Stopping a GLP-1?

Wed, 09 Sep 2026 12:00:00 +0000

Semaglutide and tirzepatide are prescription medications that lower blood sugar and body weight for as long as they are taken.

What Does MOTS-c Actually Do? What the Research Shows

Wed, 09 Sep 2026 12:00:00 +0000

MOTS-c is a small peptide the body already makes. It is encoded by a short reading frame inside mitochondrial DNA, the genetic material of the cell's energy-producing organelles, rather than being cut from an existing protein.

What Is Publication Bias, and How Would You Spot It?

Wed, 09 Sep 2026 12:00:00 +0000

A meta-analysis pools every study its authors can find and combines them into one estimate. That estimate is only as trustworthy as the studies feeding it, and studies do not reach publication at random.

What Does Vitamin D Actually Do for Muscle Function?

Wed, 09 Sep 2026 12:00:00 +0000

Observational studies have long linked low vitamin D levels with weaker muscle in older adults. The harder question is whether supplementing with vitamin D changes muscle function, and the largest pooled trials say it does not.

Does Cold Water Immersion Actually Aid Recovery?

Wed, 09 Sep 2026 12:00:00 +0000

Ice baths are one of the most visible recovery rituals in sport. Whether they actually help depends on what recovery is supposed to mean: feeling less sore tomorrow, performing well the next day, or building strength and muscle over weeks.

What Is a Receptor Agonist?

Wed, 09 Sep 2026 12:00:00 +0000

Receptor agonist is one of the most common phrases in peptide science and one of the least explained. GLP-1 receptor agonist. Ghrelin receptor agonist. Melanocortin receptor agonist.

Do GLP-1s Work Differently in Older Adults?

Wed, 09 Sep 2026 12:00:00 +0000

Semaglutide and tirzepatide are prescription medications, and the trials that led to their approval were general obesity and diabetes trials.

What Does SS-31 Actually Do? What the Research Shows

Wed, 09 Sep 2026 12:00:00 +0000

SS-31, known clinically as elamipretide, is a synthetic peptide only four amino acids long. It was designed to concentrate inside the inner mitochondrial membrane and bind cardiolipin, a lipid mitochondria need to produce energy efficiently.

Why Do Two Meta-Analyses on the Same Question Disagree?

Wed, 09 Sep 2026 12:00:00 +0000

Systematic reviews rank high because they pool many trials. But pooling does not guarantee agreement. Two careful teams can build different reviews from overlapping trials and land on opposite conclusions.

Do Collagen Peptides Do Anything for Muscle or Joints?

Wed, 09 Sep 2026 12:00:00 +0000

Collagen peptides are short fragments of collagen, the structural protein in tendon, skin and cartilage. The research on what they do for muscle and joints is genuinely split, and this article will not pretend otherwise.

Which Tendinopathy Treatments Have the Strongest Evidence?

Wed, 09 Sep 2026 12:00:00 +0000

Tendinopathy, a painful and overloaded tendon, attracts an unusually wide menu of treatments: loading exercise, corticosteroid injections, platelet-rich plasma, shockwave devices and more.

What 'Off-Label' Means

Wed, 09 Sep 2026 12:00:00 +0000

'Off-label' sounds like a warning, and sometimes it is. But the phrase describes a regulatory category, not a judgment about whether a use is wise.

Does Protein Intake Preserve Lean Mass While Losing Weight?

Wed, 09 Sep 2026 12:00:00 +0000

When people lose weight, some of what they lose is lean mass rather than fat. A long-standing question in nutrition research is whether eating more protein than the standard recommended daily allowance changes that.

What Does Tirzepatide Actually Do? What the Research Shows

Wed, 09 Sep 2026 12:00:00 +0000

Tirzepatide is a synthetic 39-amino-acid peptide that activates two gut-hormone receptors at once: GIP and GLP-1. Older drugs in the class, semaglutide, liraglutide and dulaglutide, act on GLP-1 alone.

How to Read ClinicalTrials.gov

Wed, 09 Sep 2026 12:00:00 +0000

ClinicalTrials.gov exists so that anyone can find out that a study was registered, what it planned to measure and, ideally, what it found.

Does BPC-157 Do Anything for Muscle?

Wed, 09 Sep 2026 12:00:00 +0000

BPC-157 is a synthetic fifteen-amino-acid peptide, a fragment of a protein found in human gastric juice. It is not approved for human use, and almost everything known about it and muscle comes from rats.

What Does Retatrutide Actually Do? What the Research Shows

Wed, 09 Sep 2026 12:00:00 +0000

Retatrutide, also known as LY3437943, is a synthetic peptide developed by Eli Lilly that activates three hormone receptors at once: GIP and GLP-1, the two targeted by tirzepatide, plus the glucagon receptor.

What Happens to Blood Sugar After Stopping a GLP-1?

2026-08-30

In the tirzepatide withdrawal trial that tracked this directly, HbA1c drifted upward in step with how much weight came back — from a 0.14 percentage-point rise in people who regained the least, to a 0.35 point rise in people who regained 75% or more of their treatment-phase weight loss. Fasting insulin resistance rebounded even faster. A review pooling over 289,000 patients across observational cohorts estimates glycemic, blood pressure, and lipid markers drift back toward baseline within about a year of stopping. But the two largest randomized withdrawal trials both excluded people who actually had type 2 diabetes — so the cleanest data on this question comes from a population that wasn't diabetic to begin with.

What Does the Research Actually Show About BPC-157 and Tendon Healing?

2026-08-30

Every study showing BPC-157 speeds tendon repair was done in rats. Across more than a dozen experiments — mostly from one research group at the University of Zagreb since 2003 — the peptide improved Achilles tendon strength, tendon-to-bone healing, and ligament repair in rodent models. Exactly one verifiable human trial of BPC-157 has ever been registered: a 2015 safety study in 42 healthy volunteers that finished in 2016, is still listed as Unknown status, and never reported a result.

Cerebrolysin: What Has Actually Been Trialled?

2026-08-30

A registry search this session found 42 trials of Cerebrolysin — a porcine-brain-derived peptide mixture — spanning stroke, vascular dementia, Alzheimer's disease, traumatic brain injury, Down syndrome, Bell's palsy, CADASIL, COVID-19-related smell loss, ICU delirium prevention, and even hair repigmentation. The largest single trial, a 1,070-patient acute ischemic stroke study called CASTA, found no significant difference from placebo on its primary combined endpoint, though a post-hoc subgroup of the most severely affected patients showed a mortality trend favoring Cerebrolysin. A 2013 Cochrane review of 597 vascular dementia patients across six trials found modest cognitive improvement over placebo but concluded there was still insufficient evidence to recommend routine use. Many of the trials in the registry are sponsored by Ever Neuro Pharma GmbH, the drug's manufacturer.

Do Collagen Peptides Do Anything for Muscle or Joints?

2026-08-30

The literature disagrees with itself. In a 12-week resistance-training trial, sarcopenic men gained more fat-free mass with collagen peptides than placebo (+4.2 kg vs +2.9 kg), and a 2024 meta-analysis of 19 trials found small-to-moderate benefits for fat-free mass and strength. But a controlled feeding study found collagen — unlike whey or pea protein at the same dose — did not raise muscle protein synthesis at all in older men. Joint pain shows the same split: one 191-person trial found a specific collagen type reduced knee osteoarthritis pain more than placebo and more than glucosamine-chondroitin, while a separate 167-person trial found collagen peptides reduced self-reported knee pain no more than placebo. Both directions are published in peer-reviewed journals.

Do GLP-1s Affect Bone Density?

2026-08-30

The published meta-analyses disagree with each other. A 25-study pooled analysis in people with type 2 diabetes found GLP-1 receptor agonists were linked to improved hip and spine bone density and no increased fracture risk. A separate 7-study meta-analysis of the same drug class found no significant change in bone density at all — but a significant rise in a marker of bone breakdown. A Danish trial found liraglutide alone lost more hip and spine density than exercise alone, despite similar weight loss. Almost none of this evidence comes from people taking these drugs for obesity without diabetes, and almost none of it comes from older adults, where the stakes are highest.

Do GLP-1s Affect Heart Health?

2026-08-30

In the SELECT trial — 17,604 adults with obesity and preexisting cardiovascular disease, but not diabetes — semaglutide reduced the combined rate of cardiovascular death, non-fatal heart attack, and non-fatal stroke from 8.0% to 6.5% over a mean follow-up of 39.8 months (hazard ratio 0.80, P<0.001). That is real evidence of cardiovascular benefit, not just weight loss, in people who already had heart disease. It has not been tested in people without existing cardiovascular disease, and no equivalent placebo-controlled cardiovascular outcomes trial has been completed for tirzepatide.

Do GLP-1s Work Differently in Older Adults?

2026-08-30

In the largest post hoc analyses available, weight loss and cardiometabolic improvements with tirzepatide were broadly similar in adults 65 and older compared with younger adults, and adverse event rates were not meaningfully higher. But older adults were more likely to stop treatment because of side effects, and almost none of the underlying trials were designed around this age group — they enrolled older adults incidentally, then sliced the data afterward. Dedicated trials built specifically to test sarcopenia risk, frailty, and physical function in older adults on these drugs are only just getting started, and the largest completed one so far enrolled 20 people.

Do Omega-3 Supplements Improve Cognition?

2026-08-30

The largest, longest randomized trials say no. A 2012 Cochrane review pooling 4,080 participants across three trials found no difference in Mini-Mental State Examination scores between omega-3 and placebo. The 1,525-person MAPT trial found 3 years of 800 mg DHA + 225 mg EPA daily produced no significant cognitive benefit, alone or combined with a lifestyle intervention. The 2,911-person Alpha Omega Trial found no reduction in cognitive decline risk after 40 months in heart disease patients (RR 1.03). The 3,501-person AREDS2 trial found omega-3 supplementation changed cognitive test scores by the same amount as no supplementation at all. Yet a 2023 scoping review of 78 randomized trials found 43.6% reported at least one positive cognitive outcome — which is closer to where the supplement marketing narrative comes from than to what the largest, best-designed trials actually found.

Do Stem Cell Injections Work for Joint Injury?

2026-08-30

The evidence is real but thinner and more mixed than the marketing suggests. Almost all of it comes from knee osteoarthritis, not acute joint injury, and most of the underlying trials are small — of 124 mesenchymal stem cell (MSC) trials registered for knee osteoarthritis on ClinicalTrials.gov, the majority are early-phase with fewer than 100 participants, several never reported results, and some were withdrawn. Pain improvement shows up fairly consistently across meta-analyses: a 2026 review of 6 randomized trials (551 patients) found significant reductions in pain and WOMAC scores through 12 months, and a 2024 meta-analysis found MSC injections beat hyaluronic acid on pain, function, and MRI cartilage scores at 12 months. But a broader 2026 meta-analysis of 28 trials found pain improved while overall function (WOMAC), quality of life, and MRI-based structural scores did not — concluding MSC therapy looks 'symptom-modifying rather than structure-modifying.' Local reactions like injection-site pain and joint swelling were consistently more common with MSC than control.

Does Blue Light Before Bed Actually Affect Sleep?

2026-08-30

The mechanism is real: blue-enriched light can suppress melatonin and shift circadian timing under tightly controlled lab conditions. But the consumer-facing claim — that blue-light-blocking glasses meaningfully improve your sleep — rests on thin ground. A 2023 Cochrane review of 17 randomized trials found the evidence for any effect on sleep quality too inconsistent and low-certainty to draw a conclusion. A 2025 meta-analysis pooling 3 crossover trials of blue-light-blocking glasses found no statistically significant change in sleep onset, total sleep time, efficiency, or nighttime waking. A 20-person trial found glasses modestly improved self-reported sleep — while objectively measured sleep time trended shorter, not longer. And a controlled study found reading on a tablet for two hours before bed didn't disturb sleep at all compared to reading a physical book. The idea has a real mechanism behind it and a much weaker evidence base than its popularity implies.

Does BPC-157 Do Anything for Muscle?

2026-08-30

Almost everything known about BPC-157 and muscle comes from rats. A 2025 scoping review found human clinical studies of BPC-157 limited to three small pilot studies — covering knee pain, interstitial cystitis, and intravenous safety — and none of them tested muscle. A 2026 review of six emerging peptides found that two-thirds of all published musculoskeletal research on this compound class used animal models, mostly rats, and rated the human evidence as heterogeneous with 'modest improvements at best,' from studies that mostly lacked controls. In rats, transected quadriceps muscle healed faster and stronger with BPC-157 across a 72-day study. In people, no randomized controlled trial testing BPC-157 for muscle has been published.

Does CBD Help With Sleep?

2026-08-30

The trial evidence is real but modest, mixed, and much smaller than the wellness-industry claims around it. A 2-week, placebo-controlled trial of 150mg nightly CBD alone found no significant difference from placebo on insomnia severity, sleep-onset latency, or sleep efficiency — though it did find better sleep efficiency and well-being at the 2-week mark. A larger, 125-person trial of an oral CBD-terpene formulation found a small but statistically significant increase in deep and REM sleep, averaging just over 1% of the night. A THC-CBD combination oil helped 60% of participants in one small trial no longer qualify as clinical insomniacs — but a similarly dosed THC-CBD combination in a Parkinson's disease trial showed sleep, cognition, and daily-functioning scores that favored placebo, not the cannabinoid. And a larger 178-person anxiety trial using CBD alone found sleep quality improved as a secondary outcome alongside its primary anxiety benefit. The direction is inconsistent, the trials are small, and 'CBD' in these studies is rarely one consistent product or dose.

Does Cold Water Immersion Actually Aid Recovery?

2026-08-30

For soreness, modestly and briefly: a meta-analysis of 32 trials found cold therapy reduced muscle soreness within 24 hours of exercise but not beyond it. For strength and power recovery, a 22-trial meta-analysis found no meaningful effect on maximal strength and a transient drop in jump performance immediately after immersion. For long-term training adaptation, the evidence is more concerning: in one 12-week strength-training trial, the group that used active recovery instead of cold water immersion gained significantly more muscle and strength, and a second trial found cold water immersion cut post-training muscle-fiber growth roughly in half even though strength gains were preserved.

Does Collagen Supplementation Help Tendons or Joints?

2026-08-30

Tendon studies are split by outcome. Trials that measured tendon size or the amount of collagen laid down after resistance training tend to find a benefit from collagen peptides — one 14-week trial found Achilles tendon cross-sectional area grew 11.0% with collagen versus 4.7% with placebo. But trials measuring tendon stiffness or strength usually find no difference between collagen and placebo, and one well-controlled 15-week trial found no benefit on any tendon outcome at all. Joint pain in osteoarthritis looks more consistently positive: an 11-trial meta-analysis of 870 people found collagen improved both pain and function scores over placebo. But when collagen was tested against exercise therapy head-to-head in athletes with early knee arthritis, exercise did most of the work.

Does Creatine Do Anything for the Brain?

2026-08-30

It depends heavily on who's taking it. A 2023 meta-analysis of eight randomized controlled trials found creatine improved memory overall (standardized mean difference 0.29), but the effect was large in adults aged 66-76 (SMD 0.88) and close to zero in adults aged 11-31 (SMD 0.03). The largest single trial to date — 123 adults, 6 weeks per arm — found only a borderline effect on working memory (p=0.064) and none on fluid intelligence (p=0.327), with more side effects on creatine than placebo. A 36-person trial in perimenopausal and menopausal women found a medium creatine dose improved reaction time and raised frontal-lobe brain creatine by 16.4% versus 0.9% for placebo. In healthy 10- to 12-year-olds, a week of supplementation changed neither brain creatine nor test scores.

Does Creatine Still Work After 50?

2026-08-30

Yes, but with real limits. A 2025 meta-analysis of 69 trials and 1,937 participants found creatine plus resistance training significantly increased squat strength by a pooled 5.64 kg and bench/chest press strength by 1.43 kg compared with placebo — but when the researchers split the data by age, those strength gains were significant in younger adults and not in older adults. Separate trials in frail or postmenopausal older women found creatine added nothing measurable on top of resistance training alone for muscle mass, and two years of daily creatine did not improve bone density in 200 postmenopausal women. Creatine appears to work after 50, but its effect is smaller, less consistent, and more dependent on resistance training than in younger adults.

Does Curcumin Do Anything for Inflammation?

2026-08-30

It can — but the formulation matters enormously, and the inflammation evidence itself is mixed. Curcumin's core problem is well documented: it's poorly absorbed, rapidly metabolized, and rapidly eliminated, so plain curcumin barely reaches the bloodstream. Head-to-head pharmacokinetic trials found bioavailability-enhanced formulations produced 23- to 144-fold higher blood levels than standard curcumin or turmeric extract. Using those enhanced formulations, several randomized trials found real reductions in CRP and inflammatory cytokines — a 2015 meta-analysis pooled a 2.20 mg/L drop in CRP versus placebo. But not every trial agrees: a 2026 meta-analysis of nanocurcumin in type 2 diabetes found no significant CRP reduction, and a knee osteoarthritis trial found curcumin's symptom improvement wasn't explained by any measurable drop in inflammatory markers.

Does DSIP (Delta Sleep-Inducing Peptide) Actually Affect Sleep?

2026-08-30

DSIP has been studied on and off since the 1970s, but the human evidence is thin. The one placebo-controlled trial retrieved this session — a 1992 double-blind study of 16 chronic insomniacs — found DSIP produced slightly better polysomnographic sleep efficiency and shorter sleep latency than placebo, but the authors concluded the effect was weak and 'not likely to be of major therapeutic benefit.' A single 1987 case report described DSIP correcting a delayed sleep phase in one patient. No trials of DSIP, under any name, are currently registered on ClinicalTrials.gov. A 2006 review in the Journal of Neurochemistry called the DSIP-sleep hypothesis itself 'extremely poorly documented and still weak,' and the newest research located this session is a 2021 animal study testing DSIP for stroke recovery in rats — not sleep, and not humans.

Does Exercise Improve Thinking, or Just Mood?

2026-08-30

The two effects are not the same size. A 2016 meta-analysis of 25 randomized trials found exercise had a large antidepressant-sized effect on depression (standardized mean difference 1.11, adjusted for publication bias). But a 2024 meta-analysis of 16 long-term trials (11,402 participants) found exercise alone, sustained for a year or more, produced only a small, non-significant effect on global cognition in older adults (SMD 0.05); only when combined with other interventions did the effect reach significance (SMD 0.09). Specific exercise types tell a more encouraging story: 6 months of resistance training preserved Alzheimer's-vulnerable hippocampal brain regions for a full year after training stopped in adults with mild cognitive impairment, and a poststroke cardiorespiratory exercise trial improved executive function scores at 12 months even though it didn't preserve hippocampal volume.

Does HMB Preserve Muscle During Weight Loss or Bed Rest?

2026-08-30

The answer splits by setting. During strict bed rest, HMB looked protective: in one trial, healthy older adults confined to bed for 10 days lost 2.05 kg of lean body mass on placebo but only 0.17 kg with HMB, and a meta-analysis of 7 randomized trials found an average 0.35 kg greater muscle-mass gain with HMB versus control in adults 65 and older. During intentional weight loss, the picture reversed: in patients losing weight after bariatric surgery, an HMB-enriched supplement preserved no more fat-free mass than a standard high-protein comparator, and a short-peptide-based formula outperformed the HMB-enriched one at limiting muscle loss. A small trial in boxers cutting weight for competition did find HMB preserved fat-free mass better than placebo over 6 days.

Does Magnesium Help You Sleep?

2026-08-30

A 2021 systematic review pooling 3 randomized controlled trials in 151 older adults found oral magnesium reduced sleep onset latency by 17.4 minutes compared to placebo, though total sleep time did not significantly improve and the reviewers rated the underlying evidence low to very low quality. A separate 2012 double-blind trial of 46 elderly adults given 500 mg/day of magnesium for 8 weeks found improved insomnia severity scores, sleep efficiency, and sleep onset latency, plus lower serum cortisol and higher serum melatonin. But magnesium hasn't performed as well everywhere: randomized trials testing it for nocturnal leg cramps, fibromyalgia, and post-surgical pain found no significant sleep benefit over placebo when sleep was a secondary outcome. More than 60 trials touching magnesium and sleep or insomnia are currently registered on ClinicalTrials.gov, several still recruiting.

Does Protein Intake Preserve Lean Mass While Losing Weight?

2026-08-30

A 2020 meta-analysis of 18 randomized trials found that eating more protein than the RDA (0.8 g/kg/day) preserved an extra 0.36 kg of lean mass during energy restriction, and 0.77 kg when combined with resistance training — but made no measurable difference in people who weren't dieting or training. A controlled feeding trial found whey protein blunted the post-meal decline in a marker of muscle-building activity by roughly two-thirds compared with soy or carbohydrate during a 14-day diet. All of this evidence comes from general dieting studies — none of it was tested in people losing weight on semaglutide or tirzepatide. The first trial built to test protein specifically during incretin therapy is still enrolling.

Does Protein Timing Matter, or Just Total Intake?

2026-08-30

In controlled trials that held total daily protein constant and only changed how it was spread across meals, spreading it out did not produce more muscle or strength. An 8-week resistance-training trial found no significant difference in lean mass, muscle thickness, or strength gains between eating high-protein meals three times a day versus five times a day. A 9-day controlled feeding trial found no difference in muscle protein synthesis rates across four different meal-distribution patterns. A separate trial that instead varied the total daily amount — while keeping meal pattern fixed at just two meals a day — found that a higher total dose (1.5 g/kg/day) produced significantly better whole-body protein balance than a lower one (0.8 g/kg/day). Large observational studies are more mixed: some tie meal-by-meal protein frequency to more muscle and strength, while others find total intake predicts muscle mass and per-meal frequency does not.

Does Resistance Training Protect Muscle During GLP-1 Weight Loss?

2026-08-30

The only completed randomized trial to combine supervised exercise with a GLP-1 drug found the combination cut body-fat percentage roughly twice as much as either liraglutide or exercise alone (-3.9 vs -1.9 vs -1.7 percentage points), and cut post-treatment weight regain by 6 kg compared with the drug alone. But that trial tested general supervised exercise, not resistance training specifically — no completed randomized trial has isolated resistance training's effect on muscle during semaglutide or tirzepatide therapy. A dedicated trial designed to answer that exact question is enrolling now, with results not yet available.

Does Resistance Training Work as Well After 60?

2026-08-30

Yes, including in people far older than 60. In one of the earliest controlled trials, ten nursing-home residents averaging 90 years old gained 174% in knee-extensor strength after just 8 weeks of high-intensity training, though muscle size grew far less than strength did. Meta-analyses of dozens of later trials confirm resistance training reliably improves strength and muscle mass in older adults. But it is not identical to training at 25: a lab study found the cellular machinery that turns a workout into new muscle protein activates in younger muscle after exercise and fails to activate, on the same tests, in older muscle — and not every physical-function outcome (like gait speed) improves as reliably as strength does.

Does Sleep Quality Affect Tissue Repair and Injury Risk?

2026-08-30

For injury risk, the evidence is consistent: adolescent athletes sleeping under 8 hours a night had 1.7 times the odds of injury compared with those sleeping 8 or more, and a meta-analysis of 7 studies found chronically poor sleepers had 1.58 times the odds of sports injury. A 2025 study tracking 339 runners weekly for 6 months found poor sleep quality raised running-injury risk by 36%. For tissue repair specifically, direct human evidence is thinner: the closest data comes from a study of soldiers under combined sleep, calorie, and exercise stress, where growth-hormone and testosterone signaling dropped — but that trial can't isolate sleep's individual contribution. No retrieved study measured tissue-repair biomarkers under sleep restriction alone in otherwise unstressed humans.

Does Stretching Prevent Injury?

2026-08-30

The largest pooled analysis of the question — a systematic review of comparative injury-prevention studies — found stretching was not significantly associated with reduced injury risk (odds ratio 0.93, 95% CI 0.78-1.11). A randomized trial of 1,538 army recruits found the same: no significant reduction in lower-limb injuries from a supervised pre-exercise stretching routine over 12 weeks. Stretching does reliably improve flexibility — static stretching produced the largest range-of-motion gains of any method tested in one large meta-analysis — but it was eccentric strength training, not stretching, that cut hamstring injury rates by more than half in the same body of evidence. One meta-analysis also found static stretching temporarily worsens balance compared with dynamic stretching.

Does Testosterone Therapy Build Muscle in Older Men?

2026-08-30

It depends on who was studied and what was measured. In frail, obese, hypogonadal men on a 6-month weight-loss program, testosterone preserved more lean mass and thigh muscle volume than placebo (-2% vs -4% loss, p=0.04) but did not add extra strength beyond diet and exercise alone (23% vs 22% gain, p=0.94). In mobility-limited older men with low-normal testosterone, testosterone gel did increase strength more than placebo — but the trial's safety monitors stopped enrollment early after adverse events rose in the testosterone group. In healthy, non-hypogonadal older men doing resistance training, testosterone injections increased both muscle mass and strength gains beyond training alone. A separate trial found lean mass increased only with an aromatase inhibitor, not with testosterone gel directly, complicating the simple story that more testosterone means more muscle.

Does GHK-Cu Do Anything for Skin or Wound Healing?

2026-08-30

GHK-Cu has a genuine, decades-old mechanistic story in cell cultures and animal wounds — it does stimulate collagen and glycosaminoglycan synthesis in isolated human fibroblasts and speeds wound contraction in diabetic rats. But the only completed randomized trial in actual humans tested it as a post-laser skin cream in 13 patients, and blinded evaluators found no significant difference in wrinkle improvement or erythema resolution; only a patient-satisfaction questionnaire favored it. A Phase 2 trial testing GHK-Cu directly on a real wound in humans only opened for recruitment in 2026, is still enrolling, and has not reported results. One older animal study, in guinea pigs, actually found GHK-Cu delayed skin reorganization rather than speeding it.

How Long Do People Actually Stay on GLP-1s?

2026-08-30

Considerably less long than clinical trials suggest. In a large US commercial insurance claims analysis, only 32.3% of people starting a GLP-1 for obesity were still on it at one year, and persistence varied enormously by drug — 47.1% for semaglutide versus 19.2% for liraglutide in the same dataset. In a German digital weight-loss program, 88% of patients had dropped out of the medication-and-tracking protocol within 12 months, even with structured support. A US academic obesity clinic offering the drugs at no cost to patients still saw a median persistence of well under a year. Every real-world cohort checked lands in roughly the same place: most people don't stay on these drugs as long as the trials that established their benefits.

How Long Does Soft Tissue Actually Take to Heal?

2026-08-30

Much longer than the visible symptoms suggest, and the timeline varies enormously by tissue type. General soft tissue healing runs through an inflammatory phase and a proliferative phase lasting days to a few weeks, followed by a remodeling phase that unfolds over months as collagen reorganizes. Tendon is described the same way, but a classic review notes the biochemical and mechanical properties of healed tendon never fully match intact tendon, even after remodeling is 'complete.' Ligament graft tissue takes even longer: human biopsy data on ACL reconstruction grafts found cell counts and collagen structure were still significantly different from native ligament more than 9 years after surgery. At the injury-severity end, a small pilot study found simple ankle sprains returned professional athletes to play in a mean of 26 days versus 91 days for a more severe 'high' ankle sprain, while a separate cohort following ankle ligament reconstruction surgery found a mean return-to-sport time of 172 days — and only about half of patients had returned by then.

How Much Protein Do Older Adults Actually Need?

2026-08-30

In a 6-month controlled-feeding trial, older men whose usual intake already met the standard recommendation (0.8 g/kg/day) saw no additional lean-mass benefit from raising it to 1.3 g/kg/day (difference 0.31 kg; 95% CI -0.46 to 1.08; p=0.43). But in sarcopenic older adults specifically, reaching 1.2-1.5 g/kg/day — whether through diet counseling or a supplement — was linked to measurable gains in muscle mass index that a lower intake did not produce. A separate feeding study found that once total intake exceeded the recommendation, the source mattered: whey and pea protein raised the body's muscle-building signal, while collagen at the same amount did not. No trial in this search tested protein needs specifically in adults 85 and older.

How Small Is Too Small? Sample Size, Explained

2026-08-30

Sample size determines what a study can detect, not just how confident it can be. Early dose-finding work on the growth-hormone secretagogue MK-677 tested groups of just 10-12 healthy elderly adults and found a clear, statistically significant rise in bone-turnover markers — a large, easy-to-detect biochemical signal. A later 161-patient trial of the same peptide in hip-fracture patients found IGF-I levels jumped 84% versus 17% on placebo (clearly significant, non-overlapping confidence intervals) — but functional recovery, the outcome patients actually cared about, showed no significant difference, despite favorable trends. The study's own authors said functional measures may not be responsive enough for a trial that size. Contrast that with the SELECT trial, which enrolled 17,604 people specifically because the real effect it was chasing was small.

How to Read a Clinical Trial

2026-08-30

A trial is built around one endpoint chosen before it starts — everything else is secondary, and secondary results don't carry the same weight even when a headline treats them that way. In a 2007 trial of the growth-hormone-releasing peptide tesamorelin, 412 people with HIV-related abdominal fat were randomized to drug or placebo; the pre-specified primary endpoint, percent change in visceral fat on CT scan, fell 15.2% on tesamorelin versus a 5.0% rise on placebo (P<0.001). A pooled 806-patient analysis of the same drug measured a second fat depot too — subcutaneous fat barely moved and missed significance (P=0.08). Reading a trial well means finding the primary endpoint, checking every other result instead of just the ones that succeeded, and reading the safety table as carefully as the results everyone quotes.

How to Read ClinicalTrials.gov

2026-08-30

A registry listing is a snapshot, not a verdict — five fields do most of the work: status, primary completion date, whether results have been posted, the sponsor, and enrollment. BPC-157's only completed human trial (NCT02637284, 42 people, finished dosing in 2016) has sat at Unknown status for roughly a decade with no results ever filed. A 320-person Phase 2 ipamorelin trial (NCT01280344) shows the same gap despite reaching Completed status. By contrast, semaglutide's STEP 1 trial (NCT03548935, 1,961 people, sponsored by Novo Nordisk) completed on schedule and does show posted results — a useful benchmark for what a fully reported trial record looks like.

How to Spot a Bad Health Claim

2026-08-30

Four real examples make the pattern checkable. A 1996 pilot trial of knee surgery for osteoarthritis enrolled just 10 patients — too few, its own authors wrote, to draw any valid statistical conclusion. A 2002 follow-up trial of 180 patients, this time with a real placebo-surgery control group, found the fake operation worked just as well as the real one for two full years. A deliberately tongue-in-cheek 2012 New England Journal of Medicine analysis found a near-perfect correlation (r=0.791, p<0.0001) between a country's chocolate consumption and its Nobel Prizes per capita — an intentionally absurd illustration of mistaking correlation for causation. And internal industry documents published in 2016 showed the Sugar Research Foundation secretly funded a 1965 literature review that downplayed sugar's role in heart disease and pointed the blame at fat instead. None of these facts alone makes a claim false. Each is a specific, checkable question a strong claim should survive.

Is 'Brain Fog' a Real, Measurable Thing?

2026-08-30

'Brain fog' has no formal diagnosis, no ICD or DSM code, and no single validated test — researchers borrow the term patients use and then measure whatever they can. Under that umbrella, real things get found: a meta-analysis of 13,232 people pooled from 81 studies found 22% reported cognitive impairment 12+ weeks after COVID-19. A narrower analysis using the term 'brain fog' specifically, across 19 studies and 11,324 patients, put the figure at 32% — but with a confidence interval spanning 9% to 55%, reflecting how differently studies define and measure it. In several conditions — celiac disease, HIV, functional cognitive disorder — people's self-reported fog and their scores on objective cognitive tests frequently don't match, in both directions. The complaint is consistently real. What it's tracking is still contested.

Is 'Food Noise' a Real, Measurable Thing?

2026-08-30

It started as a patient-coined term with no formal clinical definition, and researchers are still building the tools to measure it. A 550-person retrospective survey using a new 5-item Food Noise Questionnaire found scores roughly halved after starting semaglutide. A small controlled lab study found the same drop after 6 months, alongside a measurable shift in sweet-taste detection. A validated, decades-older instrument — the Control of Eating Questionnaire — shows durable reductions in food cravings through two years in a large randomized trial. But a small real-world cohort using yet another validated scale found cravings essentially unchanged. The underlying construct is real enough that multiple research groups are now racing to standardize how to measure it — which also means, as of today, there isn't one settled way to measure it.

Is 'Muscle Memory' Real?

2026-08-30

The idea comes from animal research: in mice and rats, muscle cells that gained extra nuclei during a period of overload training kept those nuclei even after severe atrophy, which researchers proposed as a cellular memory mechanism. Human replication is contested. One small human trial (12 people) found a similar pattern over 16 weeks of detraining — but even that study couldn't show the retained nuclei produced faster regrowth when the muscle was retrained. A larger analysis pooling 147 human and animal studies concluded that human muscle nuclei are not permanent — they are lost with atrophy and with aging — and that the mouse-based theory does not hold up cleanly in people. A newer, separate line of human research points to a different mechanism entirely: retained chemical marks on DNA, not retained nuclei.

What Happens to Muscle During Bed Rest or Immobilisation?

2026-08-30

It starts fast and keeps compounding. In one trial, young men lost 3.5% of quadriceps cross-sectional area and 9.0% of knee-extensor strength after just 5 days of one-legged immobilization; by 14 days in the same trial design, the losses had grown to 8.4% of muscle area and 22.9% of strength. A separate 10-day trial in young women found a much steeper 41.6% strength loss over a similar timeframe, underscoring how much the exact numbers can vary between studies, sexes, and testing methods. A small amount of resistance exercise during immobilization blunted the losses in one trial. But even a sophisticated 60-day bed-rest countermeasure combining exercise and artificial gravity did not fully protect contractile muscle function, despite preserving other tissue and metabolic measures.

Do NSAIDs Slow Tendon and Bone Healing?

2026-08-30

In rat surgical models, both selective and non-selective NSAIDs consistently and significantly weakened healing tendon-to-bone repairs — in one 180-rat study, both indomethacin and celecoxib produced significantly lower failure loads than untreated controls at every time point measured, and 5 of 120 NSAID-treated tendons failed to heal at all. But the human evidence on bone is much weaker: a systematic review of 16 human studies covering nearly 13,000 patients found the data too inconsistent in quality and design to support a clear recommendation, and a large 309,330-fracture database study tied elevated nonunion risk specifically to combined NSAID-plus-opioid use, not NSAID use alone. No human trial has directly tested whether NSAIDs weaken a healing tendon the way they do in rats.

How Does Poor Sleep Affect Metabolic Health?

2026-08-30

Faster than most people assume. In postmenopausal women, cutting sleep to 60% of normal for just 4 nights reduced insulin sensitivity by 12-20% depending on insulin dose, in a randomized crossover trial. In young men, 4 nights of sleep restricted to 4 hours induced significant hyperinsulinemia, hyperglycemia, and insulin resistance — and clamping cortisol and testosterone at normal levels cut that insulin-resistance effect roughly in half, pointing to a specific hormonal pathway. In women followed for 6 weeks, sleep cut by an average of 1.3 hours per night raised fasting insulin and a standard insulin-resistance score, with the effect stronger after menopause. Even in isolated fat cells taken from sleep-restricted volunteers, the insulin dose needed to trigger a normal signaling response was nearly three times higher after just 4 nights of short sleep. These are small, short, tightly controlled trials — but they consistently point the same direction, in men, women, and isolated tissue alike.

Preprints, Peer Review, and What the Difference Is Worth

2026-08-30

A preprint is a study posted publicly before independent experts have scrutinized it — and a meaningful share never complete that step at all. Of 5,061 COVID-19 preprints posted in early 2020, only 5.7% had appeared in a peer-reviewed journal by the time researchers checked. Of 1,471 orthopaedic preprints posted from 2014-2021, 52% were later matched to a peer-reviewed publication. And peer review isn't a rubber stamp for the ones that make it: in a study matching 21 preprints of COVID-19 critical-care therapy trials to their published versions, 33% changed a primary outcome's effect measure, 24% changed the statistical significance of a secondary outcome, and 19% changed the study's stated conclusion between the two versions.

What Is the Evidence for PRP in Tendon Injury?

2026-08-30

The largest sham-controlled trial ever run on PRP injections for tendon pain — 240 patients with chronic Achilles tendinopathy — found no meaningful difference from a fake injection at 6 months. A 2022 meta-analysis of 33 randomized trials across six tendon conditions found PRP injections outperformed comparators in only one of them, carpal tunnel syndrome. But PRP looks more useful in a different role: as a surgical adjunct. A meta-analysis of 17 randomized trials found PRP used during rotator cuff surgery lowered the structural retear rate from 25.4% to 19.3%. The evidence for PRP as a standalone injection and PRP as a surgical augmentation point in different directions, and that gap is unresolved.

Do Racetams and Other Nootropics Have Human Evidence?

2026-08-30

The evidence is older, thinner, and more mixed than the 'smart drug' marketing implies. A 2002 meta-analysis of 19 placebo-controlled trials found piracetam produced a favorable global impression of change in patients with dementia or cognitive impairment — but a 2023 network meta-analysis of frontotemporal dementia found piracetam significantly worsened neuropsychiatric symptoms (SMD 3.48), and a 2015 review concluded it doesn't appear effective for Lewy body dementia. In healthy volunteers specifically, a small 1990 trial found aniracetam, but not piracetam, reversed drug-induced memory impairment — one of the few controlled tests of a racetam in people without cognitive impairment. A 2022 pharmacology review of 'smart drugs' concluded their benefit in healthy people is uncertain and, when present, temporary. Most racetam trials were run in the 1980s-1990s, in small and often elderly clinical samples, not in the healthy adults now taking them for cognitive enhancement.

How Much Weight Do People Actually Lose Outside of Clinical Trials?

2026-08-30

In the pivotal STEP 1 trial, semaglutide produced 14.9% average weight loss over 68 weeks (n=1,961); tirzepatide's SURMOUNT-1 trial produced up to 20.9% at the highest dose over 72 weeks (n=2,539). Real-world cohorts consistently land lower. A 2026 review comparing 127 trials against 26 real-world studies found real-world semaglutide users with diabetes lost 4.7-10.5% of body weight over 6-12 months — well below trial figures — and traced most of the gap to two things: only 13% of real-world semaglutide users ever reached the 2.4 mg trial dose, and 20-50% of people discontinue treatment within a year. Among people who stayed on treatment and reached target doses, real-world results converged much closer to trial results.

Relative vs. Absolute Risk: The Most Common Trick in Health Headlines

2026-08-30

In the SELECT trial, semaglutide reduced major cardiovascular events by 20% relative to placebo — the number most headlines led with. But using the trial's own raw event counts, 6.5% of the semaglutide group (569 of 8,803) had an event versus 8.0% of the placebo group (701 of 8,801), a difference of 1.5 percentage points. Framed as a relative risk reduction, the effect sounds sweeping. Framed as an absolute risk reduction, it means roughly 67 people would need to take semaglutide for about 3.3 years to prevent one event. Both numbers come from the same data. Neither is wrong. But they tell a reader very different things about how much benefit to expect.

Semaglutide vs Tirzepatide: What Do Head-to-Head Trials Show?

2026-08-30

One published head-to-head randomized trial exists: SURMOUNT-5, comparing the maximum tolerated doses of each drug in 751 adults with obesity. Tirzepatide produced significantly greater weight loss (-20.2% vs -13.7%) and a larger reduction in waist circumference (-18.4 cm vs -13.0 cm) over 72 weeks. That is real head-to-head evidence, not just a comparison across separate placebo trials — but it is also the only such trial, it excluded people with type 2 diabetes, and it did not test whether the larger weight loss translates into a larger cardiovascular or long-term health benefit.

Semax and Selank: What Evidence Exists Outside Russia?

2026-08-30

A ClinicalTrials.gov search run this session found zero registered trials for either Semax or Selank, under any spelling. On PubMed, the human literature for both peptides is small and almost entirely Russian: a 2007 open-label study tested Semax in 27 patients with motor neuron disease, and a 2008 trial compared Selank to the benzodiazepine medazepam (not placebo) in 62 patients with generalized anxiety disorder and neurasthenia. A 2026 review of peptide therapeutics, describing Semax and Selank alongside other 'neuroactive peptides,' concluded there is 'a current lack of clinical trials.' The evidence base for both compounds is largely non-replicated and comes from one country.

TB-500 and Thymosin Beta-4: What Has Actually Been Studied?

2026-08-30

Eighteen human trials of thymosin beta-4 have ever been registered on ClinicalTrials.gov, but they studied heart attacks, dry eye, corneal wounds, pressure ulcers, and a rare skin disease — not tendons. Only one of those 18 was registered specifically as 'TB-500,' the fragment version sold online; it opened in 2026 to study cardiovascular biomarkers, not soft-tissue injury. The tendon-healing claim behind TB-500's popularity comes from a single 2026 rat study comparing it to BPC-157 in a surgically cut Achilles tendon. No human trial has ever tested thymosin beta-4 or TB-500 on a tendon, ligament, or muscle injury.

What Actually Speeds Up Fracture Healing?

2026-08-30

Less than commonly assumed. A 2023 Cochrane review of ultrasound and shockwave therapy — the most heavily studied 'accelerant' — found moderate-certainty evidence of little or no difference in nonunion risk across 1,543 fractures, and very-low-certainty, inconsistent effects on time to union. A randomized trial of high-dose vitamin D in postmenopausal women with wrist fractures found no healing benefit and a signal of worse bone stiffness at the higher dose. Teriparatide built more bone density in osteoporotic hip fracture patients across 8 pooled trials but did not speed up the fracture healing rate itself. The clearer findings run the other direction: smoking nearly doubled nonunion risk across 69 pooled studies, and NSAIDs taken at higher doses for longer than a couple of weeks were linked to more impaired healing in adults, though not in children or with short courses.

What Do Growth Hormone Secretagogues Actually Do?

2026-08-30

Ipamorelin and CJC-1295 have never been tested in a human trial for muscle, strength, or aging outcomes — the only completed clinical trials of these two compounds studied gut motility after bowel surgery. A related GHRH analog, studied in 19 adults aged 55-71 over 5 months, raised IGF-1 and increased lean body mass, insulin sensitivity, and libido — but only in men, not women. Another secretagogue, MK-677, raised IGF-1 by up to 73% over 12 months in a 563-person Alzheimer's trial, yet produced no measurable clinical benefit on any outcome tested. The pattern across this drug class is consistent: these compounds reliably move growth hormone and IGF-1 blood levels. What that does for muscle in aging humans, specifically, is mostly untested or unproven.

What Does Caffeine Actually Do to Cognitive Performance?

2026-08-30

Under real sleep deprivation and stress, caffeine produces a genuine, dose-dependent improvement: in 68 Navy SEAL trainees after 72 hours without sleep, 200-300 mg significantly improved vigilance, choice reaction time, and learning, with the study's authors identifying 200 mg as the most effective dose in that setting. But a substantial share of caffeine's everyday 'boost' looks like withdrawal reversal rather than true enhancement. One trial found caffeine improved mood, alertness, and psychomotor performance only in habitual coffee drinkers who'd gone without it overnight — not in people who don't normally consume caffeine. A separate trial found benefits in both groups regardless of habitual use, so the two controlled studies disagree with each other. A 2010 Cochrane review of 13 trials found caffeine improved memory, attention, and perception scores but had no effect on verbal functioning and language skills. Even 9- to 11-year-old habitual caffeine consumers showed the same accuracy-restoring pattern as adults.

What Does Grip Strength Actually Predict?

2026-08-30

In a study of 139,691 adults across 17 countries, every 5 kg drop in grip strength was linked to a 16% higher risk of death from any cause and a 17% higher risk of cardiovascular death — grip strength predicted death better than systolic blood pressure did. A separate analysis of 502,293 UK Biobank participants found the same pattern held for cancer and respiratory deaths too. But the relationship isn't perfectly linear: in people with chronic kidney disease, mortality risk actually ticked back up above roughly 28 kg. No trial has tested whether training grip strength itself changes any of these outcomes.

What Does \"Research Use Only\" Actually Mean?

2026-08-30

Research Use Only is a labelling and marketing designation, not a safety or purity certification. It signals that a product has not gone through the regulatory process required to be marketed for human diagnostic or therapeutic use — nothing more. BPC-157, the most heavily marketed RUO peptide, has exactly one registered human trial in its history: a 2015 Phase 1 pharmacokinetic study (NCT02637284) that has sat at Unknown status for roughly a decade with no results ever posted. As of 2026, a small number of newly registered trials (BPC-157, TB-500, GHK-Cu) are testing these same molecules as real drug candidates for the first time — a regulatory pathway entirely separate from the vials sold online.

What Does Sleep Deprivation Do to Hormones?

2026-08-30

A series of small controlled trials in healthy young men, run mostly at the University of Chicago, found sleep restriction disrupts multiple hormone systems within days. Cutting sleep to 4 hours a night for 6 nights raised evening cortisol, lowered thyroid-stimulating hormone, and reduced glucose tolerance in 11 men. Two nights of sleep restriction in 12 men lowered the appetite-suppressing hormone leptin by 18% and raised the appetite-stimulating hormone ghrelin by 28%, alongside a 24% jump in self-reported hunger. One week of 5-hour nights lowered daytime testosterone by 10-15% in 10 young men, alongside falling vigor scores. And when researchers experimentally held cortisol and testosterone artificially steady during sleep restriction in 34 men, the resulting insulin resistance was cut roughly in half — evidence that these hormone shifts are not just a side effect of sleep loss, but part of the mechanism by which it damages metabolism.

What 'Statistically Significant' Actually Means

2026-08-30

A p-value answers one narrow question: if the treatment truly did nothing, how likely is a gap this large between groups to appear by chance alone? In the SELECT trial, 17,604 people with cardiovascular disease and overweight or obesity were randomized to semaglutide or placebo; a major cardiovascular event occurred in 6.5% of the semaglutide group versus 8.0% of placebo (P<0.001) — a result very unlikely to be chance. But a later subgroup analysis of the same trial found a 34% relative risk reduction in a smaller subgroup that wasn't statistically significant at all (P=0.11), while a 26% reduction in a larger subgroup was (P=0.0004). The bigger-looking number was the less certain one — significance tracks precision, not just the size of an effect.

What Does Vitamin D Actually Do for Muscle Function?

2026-08-30

In the largest pooled analysis of placebo-controlled trials — 54 studies, 8,747 people — standard vitamin D supplementation (D2 or D3) did not improve grip strength, muscle mass, or most performance tests, and on two measures (a walking-and-turning test, knee-flexion strength) the vitamin D groups did slightly worse than placebo. A separate analysis limited to postmenopausal women found the same pattern of no effect. A different, chemically activated form of vitamin D — used mainly in Japan and tested in smaller trials — did show a specific benefit: it reduced falls by 19% and improved quadriceps strength, though not grip strength or other muscle groups. The two forms of vitamin D are not interchangeable in what the trials found.

What Dose of Melatonin Do the Trials Actually Use?

2026-08-30

Across the trials pooled in recent dose-response meta-analyses, melatonin doses have ranged from roughly 1 mg up to 10 mg per night. A 2024 dose-response meta-analysis of 26 randomized controlled trials (1,689 observations, trials published 1987-2020) found melatonin's sleep-promoting effect grew with dose up to about 4 mg/day, a higher figure than the 2 mg dose commonly used in practice, and found timing — about 3 hours before bedtime — mattered as much as dose. A 2005 meta-analysis of 17 earlier trials in 284 subjects, pooling a range of doses, found melatonin cut sleep onset latency by an average of 4.0 minutes and extended total sleep time by 12.8 minutes. A Cochrane review of shift workers, where doses across the pooled trials ranged from 1 to 10 mg, explicitly found no dose-response relationship for sleep length after night shifts. This article reports the doses researchers tested — it does not recommend a dose for anyone to take.

What Happens to Metabolic Rate During Rapid Weight Loss?

2026-08-30

Across a systematic review of 33 controlled studies (2,528 participants), resting energy expenditure dropped more than body-composition changes alone could explain — a phenomenon called adaptive thermogenesis — in 82.8% of studies that measured it. In a classic controlled-feeding study, three weeks of 50% calorie restriction cut resting energy expenditure by 266 kcal/day, and roughly 72 kcal of that drop couldn't be explained by loss of tissue at all. The effect has been measured after diet-only weight loss, intermittent dieting, and bariatric surgery — but never, so far, during weight loss caused by a GLP-1 or GIP-based drug. That is a genuine, unfilled gap in the evidence.

What Is a Systematic Review, and Why Does It Outrank a Single Study?

2026-08-30

A single 1999 trial of 11,324 heart attack survivors found that fish-oil supplements cut the combined risk of death, another heart attack, or stroke by up to 15%, with cardiovascular death itself down 30% in the trial's four-way analysis. That result helped shape both clinical guidelines and a consumer supplement industry. When a 2020 Cochrane systematic review pooled 86 randomized trials and 162,796 participants asking the same question, cardiovascular mortality fell by only 8% (a much smaller, though still real, effect), and all-cause mortality showed no significant change at all. Neither result was fraudulent or wrong on its own terms — the single trial reported an honest finding from one population, in one era, on one draw of chance. Pooling every trial that asked the same question is what let researchers see whether that finding held up.

What Is an Effect Size, and Why Does It Matter More Than the P-Value?

2026-08-30

A p-value tells you how likely a result would be if there were truly no effect at all — it says nothing about how large that effect actually is. In a 1989 trial of 22,071 physicians, low-dose aspirin cut heart attack risk by 44% (p<0.00001): a result that was both statistically significant and clinically large. In a 2020 Cochrane review of 86 omega-3 trials and 162,796 participants, the reduction in coronary heart disease death was also technically significant (95% CI just barely excluding no effect) — but it worked out to a number needed to treat of 334, meaning 334 people would need to take the supplement to prevent a single death. Two 'significant' results, two very different sizes of real-world benefit.

What Is Blood Flow Restriction Training and Does It Work?

2026-08-30

Blood flow restriction (BFR) training uses an inflatable cuff on a limb to partially restrict blood flow during low-load exercise, typically around 20-40% of a person's one-repetition maximum. A meta-analysis of 10 randomized trials in athletes found BFR combined with resistance training produced meaningful gains in lower-limb strength and muscle size compared with control training. Head-to-head trials found BFR at low loads can match or nearly match heavy-load training for hypertrophy and some performance measures, though heavy loads still produced significantly greater maximal strength gains in at least one trial. The same meta-analysis found no significant improvement in sport-specific performance from adding BFR. One safety-relevant finding: inflating BFR cuffs on the legs of older adults acutely worsened their walking balance, with worse effects at higher cuff pressure.

What Is Publication Bias, and How Would You Spot It?

2026-08-30

Publication bias is the tendency for studies with positive, significant results to get published — and published faster — more often than studies that find nothing, which skews the visible literature toward exaggerated effects. Researchers test for it using funnel plots and Egger's test, a statistical check for lopsided asymmetry in how study results cluster. In a 2025 meta-analysis of weight regain after stopping anti-obesity drugs (36 studies), Egger's test flagged significant bias for one drug, liraglutide (p=0.013), but not for semaglutide, exenatide, or orlistat. A separate 2026 meta-analysis of lean mass loss during incretin therapy (20 trials, 15,782 people) ran the same test and found no evidence of bias (p=0.23). Both outcomes are normal — the test doesn't always find something, and that's part of what makes it useful.

What Is Sarcopenia and How Is It Actually Measured?

2026-08-30

Sarcopenia's clinical definition changed in 2019 to center on low muscle strength rather than muscle size, with low muscle mass used to confirm the diagnosis and poor physical performance marking severity. How common it turns out to be depends heavily on which yardstick is used: a 2025 meta-analysis of 52 studies and 70,202 older adults found reported prevalence ranging from 5.2% to 50.0%, with a pooled estimate of 18.8%. In one Hong Kong cohort, switching from a DXA scan to a bioelectrical impedance device changed a person's measured muscle mass by nearly 3 kg/m² on average. The condition is real and it predicts mortality, but exactly who has it still depends on which test, which cutoff, and whose population the cutoff was built from.

What Makes a Control Group Good — or Useless?

2026-08-30

A control group is only as good as its ability to isolate a treatment's real effect from everything else that makes people report feeling better — expectation, natural healing, extra attention from a clinician. In 2021, the largest sham-controlled trial ever run on platelet-rich plasma (PRP) injections randomized 240 patients with chronic Achilles tendinopathy to a real PRP injection or a sham injection (a needle inserted under the skin but never into the tendon), and found no meaningful difference at 6 months (adjusted score difference -2.7, 95% CI -8.8 to 3.3). Two decades earlier, a 180-patient trial did the same for knee arthroscopy, randomizing patients to real surgery or placebo surgery involving only skin incisions, and found the fake surgery worked just as well as the real one for two full years. Both trials share the same design principle: a control condition convincing enough that the patient — and often the person scoring the outcome — cannot tell which treatment they actually received.

What Side Effects Were Actually Reported in the Trials?

2026-08-30

Gastrointestinal events — nausea, vomiting, diarrhea, constipation — were consistently the most common adverse events across every major trial, and they drove treatment discontinuation in roughly 4-7% of participants in 68-72 week obesity trials, versus under 3% on placebo. In a 3-year cardiovascular trial with older, sicker participants, discontinuation for adverse events reached 16.6%. Serious adverse events, including pancreatitis and gallstones, were consistently reported as uncommon. Meta-analyses put the odds of nausea 3-6 times higher than placebo depending on dose.

Which Tendinopathy Treatments Have the Strongest Evidence?

2026-08-30

Ranked by evidence quality, progressive loading exercise comes out on top: in a 2026 network meta-analysis of patellar tendinopathy, no other intervention — including blood flow restriction training, flywheel work, or eccentric-only protocols — statistically beat heavy slow resistance training across 10 pooled trials, and a separate network meta-analysis of hip tendinopathy (greater trochanteric pain syndrome) found exercise therapy the single most effective conservative option across 19 trials and 1,701 patients. Corticosteroid injections show real short-term pain relief for tennis elbow but no significant advantage over placebo past 12 weeks. Extracorporeal shockwave therapy fared worst in the newest, most rigorous review: a 2026 meta-analysis of 9 randomized trials found no clinically meaningful benefit over sham for either midportion or insertional Achilles tendinopathy. Platelet-rich plasma's evidence is site-dependent — ranked most likely to help shoulder calcific tendinopathy in one network meta-analysis, but only 'moderate' for tennis elbow in another.

Who Funded the Study, and How Do You Find Out?

2026-08-30

Funding source doesn't make a finding right or wrong, but it's checkable, and readers rarely check it. Some journals put a structured Funding line directly in the PubMed abstract — a 2023 GLP-1 network meta-analysis names an Italian research foundation and an EU grant; a 2025 GLP-1 surgical-safety review names two NIHR fellowships. Where there's no funding line, author affiliations in the byline often show it anyway: 3 of the 14 named authors on a semaglutide trial-extension paper list a Novo Nordisk A/S affiliation, and 5 of 7 authors on a tirzepatide post-hoc analysis list an Eli Lilly and Company affiliation. ClinicalTrials.gov adds a third path — its Sponsor field names Novo Nordisk A/S directly for the STEP 1 trial, and every trial site is labeled a 'Novo Nordisk Investigational Site.'

Why Am I Still Hungry on a GLP-1?

2026-08-30

In controlled feeding trials, semaglutide cut how much food people ate at a free-choice meal by roughly 35-39% compared with placebo, and reduced self-reported hunger significantly. But the effect is not uniform: about 1 in 10 participants in obesity trials lost less than 5% of body weight, and the mechanism most people assume explains appetite loss — a slowed stomach — accounted for only 4-6% of the variation researchers could measure. No trial has identified in advance who will keep feeling hungry.

Why Do Two Meta-Analyses on the Same Question Disagree?

2026-08-30

In 2024, two separate meta-analyses asked whether GLP-1 receptor agonists — the drug class behind semaglutide and liraglutide — change bone mineral density, and reached opposite answers. One, pooling 26 randomized trials and 2,268 participants, found a statistically significant increase in lumbar spine bone density (SMD 1.04, 95% CI 0.60-1.48) and femoral neck bone density (SMD 1.29, 95% CI 0.36-2.23). The other, restricting itself to 7 randomized trials with a true placebo or untreated control arm, found no significant change in bone density at the femoral neck, hip, or spine. Both were peer-reviewed, published the same year, and drew on overlapping trial literature. The difference wasn't fraud or incompetence on either side — it was how each review defined a 'control group,' what statistic it used to express the result, and how long the underlying trials ran.

Why Does Building Muscle Get Harder With Age?

2026-08-30

Muscle loss appears to begin quietly from middle age, at roughly 1% of mass per year, and can reach around 50% of total muscle mass lost by the 8th or 9th decade of life in severe cases. Underneath that decline, researchers have documented a phenomenon called 'anabolic resistance': aging muscle mounts a smaller protein-building response to the same dose of protein or the same bout of exercise that would trigger a larger response in younger muscle. In young, trained men, 20 grams of whey protein was enough to maximally stimulate muscle protein synthesis after resistance exercise — more didn't help. Reviews describe several candidate mechanisms behind why older muscle needs more to get the same result — reduced anabolic signaling, impaired blood flow delivering amino acids to muscle, and amino acids getting retained in the gut before reaching muscle at all — but no single confirmed cause, and no agreement on whether the effect can be fully reversed.

Why 'It Worked in Mice' Usually Means Nothing

2026-08-30

BPC-157, a peptide derived from a fragment of a stomach protein, has a genuinely large animal literature behind it — a 2003 study found it fully restored a surgically severed Achilles tendon in rats, improving strength, structure, and healing at the cellular level within 14 days. But a ClinicalTrials.gov search run this session found only one verifiable human trial of BPC-157 have ever been registered, and none of them tests tendon healing. One (n=42) measured only safety and pharmacokinetics in healthy volunteers and never posted results. Another, recruiting now (n=120), tests a hamstring muscle strain — not a tendon injury. The animal evidence and the human evidence are, for practical purposes, answers to two different questions.

How Much of the Weight Lost on GLP-1s Is Muscle?

2026-08-29

Across 35 randomized trials, the median share of total weight loss coming from muscle-related measures was about 28% — but the range was enormous, from roughly 16% to 40% depending on the study. Lifestyle-only weight loss showed the same pattern in nearly half of studies. And no trial measured whether any of it affected strength or physical function.

Why Does Weight Come Back After Stopping Semaglutide?

2026-08-29

In the trial that followed people for a year after they stopped, participants regained about two-thirds of the weight they had lost. A separate trial of tirzepatide found the same pattern. Researchers describe this as evidence that obesity behaves like a chronic condition — the drug suppresses appetite while it is being taken, and appetite returns when it is withdrawn.